



## **Allena Pharmaceuticals to Present at Upcoming Investor Conferences in October**

September 25, 2018

NEWTON, Mass., Sept. 25, 2018 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced that Alexey Margolin, Ph.D., Allena's Chief Executive Officer, will present a corporate update at two investor conferences in October:

### **Ladenburg Thalmann 2018 Healthcare Conference**

**Date:** Tuesday, October 2, 2018

**Time:** 10:00 a.m. ET

**Location:** New York, NY

### **2018 Cantor Global Healthcare Conference**

**Date:** Wednesday, October 3, 2018

**Time:** 4:00 p.m. ET

**Location:** New York, NY

Live audio webcasts of both presentations will be available under "Events and Presentations" in the Investors section of the Company's website at [www.allenapharma.com](http://www.allenapharma.com). Replays of the webcasts will be available on the Allena website for 30 days following each presentation.

### **About Allena Pharmaceuticals**

Allena Pharmaceuticals, Inc. is a late-stage biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders. Allena's lead product candidate, ALLN-177, is a first in class, oral enzyme therapeutic for the treatment of hyperoxaluria, a metabolic disorder characterized by markedly elevated urinary oxalate levels and commonly associated with kidney stones, chronic kidney disease and other serious kidney disorders.

### **Investor Contact**

Hannah Deresiewicz  
Stern Investor Relations, Inc.  
212-362-1200  
[hannahd@sternir.com](mailto:hannahd@sternir.com)

### **Media Contact**

Adam Daley  
Berry & Company Public Relations  
212-253-8881  
[adaley@berrypr.com](mailto:adaley@berrypr.com)



Source: Allena Pharmaceuticals, Inc.